Allogene Therapeutics, Inc. (ALLO) Revenue 2019–2025
Allogene Therapeutics, Inc. (ALLO) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$0FY2025 · since FY2019: $0 → $0
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $22,000 | -76.8% |
| FY2023 | $95,000 | -39.1% |
| FY2022 | $156,000 | -99.9% |
| FY2021 | $114.1M | — |
| FY2020 | $0 | — |
| FY2019 | $0 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →